Christopher Langmead

Servier Drug Discovery Program Head, Drug Discovery Biology

EmailChris.Langmead@monash.edu

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Head, Servier Program in Drug Discovery
Faculty of Pharmacy and Pharmaceutical Sciences
Monash Institute of Pharmaceutical Sciences

Chris Langmead has a strong interest in drug discovery, having spent 15 years working in the pharmaceutical and biotech industry in the UK, where he led project teams to discover four pre-clinical candidate drugs and managed collaborations with academic labs and other pharmaceutical companies.

In 2012 he joined MIPS to head up a drug discovery program in collaboration with Servier Laboratories, France. He is particularly interested in GPCRs as drug targets in neurodegenerative and psychiatric disorders, but also has interest in structure-function of GPCRs and analytical receptor pharmacology, with particular reference to allosteric interactions.

Servier Program in Drug Discovery

In 2012, the Monash Institute of Pharmaceutical Sciences (MIPS) entered into a collaborative drug discovery research agreement with Les Laboratoires Servier, a leading European pharmaceutical company (http://tinyurl.com/brrztb4).

The collaboration makes use of MIPS' acknowledged world-leading capability in the identification of novel GPCR targets, in the understanding of GPCR functional biology and in the design of new chemical entities to modulate GPCR activity. MIPS has developed GPCR expertise comprising technology, research facilities and world leading scientists that enable it to conduct fundamental research, drug discovery and preclinical drug development activities on GPCR targets with therapeutic potential.

Monash teaching commitment

Lectures to 3rd year BPharmSci students in the Faculty of Pharmacy and Pharmaceutical Sciences
Supervision of Honours students in Drug Discovery Biology

Research interests

GPCR target validation, hit identification and lead optimisation
CNS drug discovery
Allosteric modulation of GPCRs
Molecular and analytical pharmacology

Research area keywords

G protein-coupled receptors
drug discovery
hit identification
high throughput screening
muscarinic receptors
neuropharmacology
analytical pharmacology
allosteric modulation
structure-function
target validation
hit-to-lead
lead optimisation
psychiatric disorders
cognitive disorders

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2016 2020

1 Active
3 Finished

Alcohol and Striatal Adaptation

Lawrence, A., Langmead, C. & Spanswick, D.

National Health & Medical Research Council (NHMRC)

1/01/17 → 31/12/20

Project: Research

NHMRC Equipment Grant - Promethion High-Definition Multiplexed Respirometry System

Sexton, P., Christopoulos, A., Wootten, D. & Langmead, C.

Monash University – Internal Faculty Contribution, Monash University – Internal Department Contribution

1/01/19 → 31/12/19

Project: Research

NHMRC Equipment Grant - FLIPR Tetra high-throughput cellular screening system

Sexton, P., Christopoulos, A., Leach, K., Gregory, K., Veldhuis, N., Poole, D. & Langmead, C.

1/01/18 → 31/12/18

Project: Research

GPR88 as a novel target for fronto-striatal dysfunction in schizophrenia

Langmead, C. & Nithianantharajah, J.

National Health & Medical Research Council (NHMRC)

1/01/16 → 31/12/18

Project: Research

Research Output 2001 2019

55 Article
4 Poster
4 Review Article
2 Abstract
4 More

Bone marrow transplantation and RNAseq analysis of Gpr21^−/− monocytes reveals reduced migratory function and downregulation of inflammatory genes

Riddy, D., Kammoun, H., Bosnyak-Gladovic, S., Ziemann, M., Summers, R., Sexton, P. M., Murphy, A. & Langmead, C., 2019. 2 p.

Research output: Contribution to conference › Abstract

6 Citations (Scopus)

Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H₃ receptor antagonists

Riddy, D. M., Cook, A. E., Shackleford, D. M., Pierce, T. L., Mocaer, E., Mannoury la Cour, C., Sors, A., Charman, W. N., Summers, R. J., Sexton, P. M., Christopoulos, A. & Langmead, C. J., 1 Jan 2019, In : Neuropharmacology. 144, p. 244-255 12 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access

File

6 Citations (Scopus)

Bitopic binding mode of an M₁ muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes ^S

Bradley, S. J., Molloy, C., Bundgaard, C., Mogg, A. J., Thompson, K. J., Dwomoh, L., Sanger, H. E., Crabtree, M. D., Brooke, S. M., Sexton, P. M., Felder, C. C., Christopoulos, A., Broad, L. M., Tobin, A. B. & Langmead, C. J., 1 Jun 2018, In : Molecular Pharmacology. 93, 6, p. 645-656 12 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access

File

4 Citations (Scopus)

Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research

Riddy, D. M., Goy, E., Delerive, P., Summers, R. J. & Langmead, C. J., 1 May 2018, In : PLoS ONE. 13, 5, 19 p., e0197177.

Research output: Contribution to journal › Article › Research › peer-review

Open Access

File

2 Citations (Scopus)

Discovery and Optimization of Potent and CNS Penetrant M₅-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold

Bender, A. M., Cho, H. P., Nance, K. D., Lingenfelter, K. S., Luscombe, V. B., Gentry, P. R., Voigtritter, K., Berizzi, A. E., Sexton, P. M., Langmead, C. J., Christopoulos, A., Locuson, C. W., Bridges, T. M., Chang, S., O'Neill, J. C., Zhan, X., Niswender, C. M., Jones, C. K., Conn, P. J. & Lindsley, C. W., 18 Jul 2018, In : ACS Chemical Neuroscience. 9, 7, p. 1572-1581 10 p.

Research output: Contribution to journal › Article › Research › peer-review